Taking the Static Out of Drug Marketing
Launching a new drug involves a complex series of decision points in multiple areas including clinical trial design, target markets, marketing mix and regulatory/reimbursement issues. The traditional marketing approach tailors strategies to specific physician and patient segments in a linear manner that can be slow in responding to unanticipated results. McKinsey has developed what it calls Dynamic Pharmaceutical Product Marketing, which is a framework that incorporates systems thinking with traditional marketing's best practices to help product companies deal more efficiently and effectively with the variables of the marketplace.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.